AI Article Synopsis
- - The study aimed to compare entrectinib with other treatments for fusion-positive non-small cell lung cancer, using a systematic review to select relevant studies featuring crizotinib and chemotherapy as comparators.
- - Indirect comparisons were made using matching adjustments based on known factors, and results showed that entrectinib led to significantly better responses and overall survival compared to crizotinib, with fewer patients discontinuing treatment due to adverse events.
- - While progression-free survival was generally similar among treatments, these findings suggest that entrectinib may offer improved outcomes, aiding in more informed treatment choices for patients.
Article Abstract
To perform indirect treatment comparisons of entrectinib versus alternative fusion-positive non-small cell lung cancer treatments. Relevant studies with crizotinib and chemotherapy as comparators of interest identified by systematic literature review were selected for matching-adjusted indirect comparison by feasibility assessment. Matching was based on known prognostic/predictive factors and scenario analyses were used for unreported confounders in comparator trials. Entrectinib yielded significantly better responses versus crizotinib in all scenarios (odds ratio [OR]: 2.43-2.74). Overall survival (hazard ratio: 0.47-0.61) and adverse event-related discontinuation (OR: 0.79-0.90) favored entrectinib. Progression-free survival was similar across treatments, except in one scenario. These results suggested improved outcomes with entrectinib versus crizotinib/chemotherapy and may help to make better informed treatment decisions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/cer-2020-0063 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Entrectinib versus crizotinib in Asian patients with ROS1-positive non-small cell lung cancer: A matching-adjusted indirect comparison.
Lung Cancer
December 2024
Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, No. 241, Huaihai West Road, Shanghai 200030, China. Electronic address:
Objectives: Entrectinib and crizotinib are the only ROS proto-oncogene 1 receptor (ROS1) tyrosine kinase inhibitors available for most Asian patients. Their efficacy has neither been compared directly in clinical trials in patients with ROS1-positive non-small cell lung cancer (NSCLC), nor indirectly in Asian populations. Thus, we aimed to provide comparative evidence of the efficacy and safety of entrectinib and crizotinib for Asian patients with advanced or metastatic ROS1-positive NSCLC.
View Article and Find Full Text PDFComprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central β-Sheet 6 [Cβ6] Mutation [L2086F]).
J Thorac Oncol
May 2024
Department of Medicine, University of California Irvine School of Medicine, Orange, California; Chao Family Comprehensive Cancer Center, Orange, California.
Article Synopsis
- ROS1 fusion-positive NSCLC is a rare subtype, making up about 1% to 2% of cases, yet many ROS1 tyrosine kinase inhibitors (TKIs) are being developed in addition to three that are already approved.
- The article categorizes ROS1 TKIs based on their structures and effectiveness against specific mutations, particularly the G2032R and L2086F mutations, to help clinicians choose the right treatment strategy.
- It suggests that cabozantinib and gilteritinib, typically used for other cancers, may be repurposed as effective ROS1 TKIs, especially for overcoming resistance linked to the L2086F mutation, and advocates for future trials to explore this potential.
Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to "False" Decreases in Renal Function.
J Thorac Oncol
January 2024
Division of Nephrology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, New York, New York.
Introduction: Select tyrosine kinase inhibitors (TKIs) used to treat oncogene-driven lung cancers also inhibit MATE-1. When MATE-1 is blocked, creatinine is retained in the serum. Elevated creatinine levels raise the specter of drug-induced intrarenal insufficiency despite the lack of true renal injury.
View Article and Find Full Text PDFEntrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations.
Cancer Chemother Pharmacol
March 2023
Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Purpose: Entrectinib is a central nervous system-active potent inhibitor of tropomyosin receptor kinase (TRK), with anti-tumor activity against neurotrophic NTRK gene fusion-positive tumors. This study investigates the pharmacokinetics of entrectinib and its active metabolite (M5) in pediatric patients and aims to understand whether the pediatric dose of 300 mg/m once daily (QD) provides an exposure that is consistent with the approved adult dose (600 mg QD).
Methods: Forty-three patients aged from birth to 22 years were administered entrectinib (250-750 mg/m QD) orally with food in 4-week cycles.
Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic gene fusion cancers.
J Comp Eff Res
October 2022
Comparative Health Outcomes, Policy, and Economics Institute, School of Pharmacy, University of Washington, Seattle, WA 98195, USA.
To extrapolate clinical trial results to estimate and compare expected progression-free and overall life years (LYs) and quality-adjusted LYs (QALYs) for larotrectinib and entrectinib in patients with colorectal cancer (CRC), soft tissue sarcoma (STS) and brain metastases prior to treatment with larotrectinib or entrectinib. A naive direct comparison of larotrectinib versus entrectinib was made using partitioned survival modeling methods from clinical trial data. Larotrectinib resulted in an additional 1.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!